SCHEMBL13618884

SCHEMBL13618884

Cc1ccc(C)c(C(=O)C[C@@H](c2ccc(CCC3CC3)cc2)C2CCCC2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
TSHR P16473 2/20 0.36
POLB P06746 1/20 0.35
DRD2 P14416 2/20 0.35
DRD4 P21917 2/20 0.35
DRD3 P35462 2/20 0.35
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
ALOX15 P16050 1/20 0.34
MAPK1 P28482 1/20 0.34
THRB P10828 1/20 0.34
ACKR3 P25106 1/20 0.34
KDM4E B2RXH2 1/20 0.33
LDLR P01130 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
ADRB3 P13945 1/20 0.33
KEAP1 Q14145 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13618875 0.99 LMNA (0.39) LMNAKMT2AMEN1TSHRPOLB
SCHEMBL13618887 0.92 HDAC1 (0.36) LMNAACKR3NPC1RAB9A
SCHEMBL13618877 0.91 HDAC1 (0.37) LMNAKMT2AMEN1ACKR3KDM4E
SCHEMBL13618879 0.83 TAS1R3 (0.37) LMNAKMT2AMEN1TSHRTP53
SCHEMBL13618893 0.82 NPC1 (0.42) KMT2AMEN1TSHRPOLBDRD2
SCHEMBL13618871 0.82 TAS1R3 (0.36) LMNAKMT2AMEN1TSHRTP53
SCHEMBL13618898 0.81 FFAR1 (0.35) KMT2AMEN1DRD2DRD4TP53
SCHEMBL13618885 0.80 HSD17B1 (0.48) LMNAKMT2AMEN1POLBMAPK1
SCHEMBL13618876 0.79 HSD17B1 (0.49) LMNAKMT2AMEN1POLBMAPK1
SCHEMBL13618881 0.74 FFAR1 (0.34) KMT2AMEN1TP53KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090286765-A1 Therapeutic Agents MERCK SHARP & DOHME (UK) LIMITED (GB) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286765-A1 Therapeutic Agents GRIA1, GRIN1, GLRA1 LMNA 3470/4885KMT2A 1209/4885MEN1 2578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.